Wise D L, McCormick G J, Willet G P, Anderson L C, Howes J F
J Pharm Pharmacol. 1978 Nov;30(11):686-9. doi: 10.1111/j.2042-7158.1978.tb13365.x.
An implantable system was developed which released sulphadiazine in mice over an extended period of time efficacious against infective challenges by Plasmodium berghei. The most successful preparation was a copolymer of L(+)-lactic acid + (+/-)-lactic acid (90 and 10% by weight, respectively) with a molecular weight of 150 000, with which sulphadiazine was mixed at 33.3% of the total weight, in a formulation as beads of 1.5 mm diameter. This preparation released sulphadiazine at a nearly constant rate over three months as measured by the appearance in urine of mice of radioactivity from [35S] sulphadiazine in transplanted material. When implanted in mice, the beads gave effective protection against repetitive (weekly) infective challenges with P. berghei by implanted beads at dosages equivalent to 57 mg kg(-1) sulphadiazine and greater over 21 weeks.
研发了一种可植入系统,该系统能在小鼠体内长时间释放磺胺嘧啶,对伯氏疟原虫的感染攻击有效。最成功的制剂是L(+)-乳酸 + (+/-)-乳酸(分别占重量的90%和10%)的共聚物,分子量为150000,磺胺嘧啶按总重量的33.3%与之混合,制成直径为1.5毫米的珠粒制剂。通过移植材料中[35S]磺胺嘧啶的放射性在小鼠尿液中的出现情况测定,该制剂在三个月内以近乎恒定的速率释放磺胺嘧啶。当植入小鼠体内时,这些珠粒在21周内以相当于57毫克/千克(-1)磺胺嘧啶及更高剂量,对每周重复的伯氏疟原虫感染攻击提供了有效的保护。